Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 20/20 | 0.77 |
| ▸ | KCNK9 | Q9NPC2 | 20/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19807786 | 0.91 | KCNK3 (0.77) | KCNK3KCNK9 | |
| SCHEMBL19807781 | 0.89 | KCNK3 (0.78) | KCNK3KCNK9 | |
| SCHEMBL18978585 | 0.87 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL22635988 | 0.86 | KCNK3 (0.60) | KCNK3KCNK9 | |
| SCHEMBL19807842 | 0.86 | KCNK3 (0.77) | KCNK3KCNK9 | |
| SCHEMBL19807738 | 0.85 | KCNK3 (0.78) | KCNK3KCNK9 | |
| SCHEMBL18952543 | 0.84 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL29432697 | 0.84 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL19807727 | 0.83 | KCNK3 (0.77) | KCNK3KCNK9 | |
| SCHEMBL19807719 | 0.81 | KCNK3 (0.78) | KCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3487856-B1 | SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE | BAYER AG (DE) | 2025-01-22 | — | — | EP | disclosed |
| EP-4452246-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A MUSCARINIC RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2024-10-30 | — | — | EP | disclosed |
| CN-118785904-A | Conjugates of TASK1/3 channel blockers and P2X3 receptor antagonists for the treatment of sleep apnea | 拜耳公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-118541153-A | Conjugates of a TASK1/3 channel blocker and a norepinephrine reuptake inhibitor for the treatment of sleep apnea | 拜耳公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-118434415-A | Conjugates of TASK1/3 channel blockers and muscarinic receptor antagonists for the treatment of sleep apnea | 拜耳公司 | 2024-08-02 | — | — | CN | disclosed |
| WO-2023118102-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A MUSCARINIC RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023118122-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A P2X3 RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | WO | disclosed |
| EP-4175954-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2023-05-10 | — | — | EP | disclosed |
| EP-3965762-A1 | COMBINATION OF AN ?2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2022-03-16 | — | — | EP | disclosed |
| US-20210024545-A1 | SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE | BAYER AKTIENGESELLSCHAFT (DE) | 2021-01-28 | — | — | US | disclosed |
| WO-2020225185-A1 | COMBINATION OF AN α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-12 | — | — | WO | disclosed |
| WO-2018015196-A1 | SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE | BAYER AKTIENGESELLSCHAFT (DE) | 2018-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024545-A1 | SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE | HYOU1, DDAH1, VDAC3 | KCNK3 145/4885KCNK9 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.